NR 553 Week 7 Technology Transfer

Grace J.
September 2, 2025September 2, 2025
CU MSN, NR-553

Student Name

Chamberlain University

NR-553: Global Health

Prof. Name

Date

Week 7: Technology Transfer

According to Padmanabhan, Amin, Sampat, Cook-Deegan, and Chandrasekharan (2010), most deaths from cervical cancer occur in low- and middle-income countries (LMICs) where access to regular gynecological screening is scarce. The challenge is worsened by the limited availability of vaccines in these regions, largely due to their high costs of production and retail pricing.

The authors highlight that manufacturing vaccines locally in LMICs could significantly reduce costs, citing successful examples from Brazil, India, and China. These countries have developed affordable and efficient vaccines that comply with international standards, making large-scale vaccination programs more accessible. As a result, international agencies such as UNICEF now source vaccines from these manufacturers to supply low-income regions.

However, the scholars emphasize that developing country vaccine manufacturers (DCVMs) require access to advanced technologies to produce such vaccines. Intellectual property rights often limit this access. While DCVMs have not yet faced severe patent restrictions, future obstacles may arise as LMICs adopt World Trade Organization (WTO) requirements under the Trade-Related Aspects of Intellectual Property Rights (TRIPS) agreement. Previously, many LMICs did not enforce patents for biopharmaceuticals, but under the new framework, vaccine producers must comply strictly with international pharmaceutical patent laws.

Despite these challenges, the authors argue that such barriers should not discourage efforts by DCVMs. Governments, regional stakeholders, and global organizations should take proactive steps to support affordable vaccine production. Academic institutions are also considered essential partners in facilitating technology transfer, as they provide research expertise and help create licensing models that do not obstruct low-cost vaccine production.

Professor Response to Post

Question: Have there been any public/private global collaborations that transcended differences to address a huge public health issue? What can we learn from these? What was the catalyst for such action?

Response:
Public-private partnerships (PPPs) have been pivotal in accelerating solutions for global health crises. According to Yaïch (2009), PPPs involve collaboration between government agencies and private organizations to pool financial and technical resources, particularly for improving health services in LMICs. Such partnerships are strongly supported by the World Health Organization (WHO), the World Bank, the United Nations (UN), UNICEF, non-governmental organizations (NGOs), and global businesses.

One of the major benefits of PPPs is their ability to bridge gaps in vaccine accessibility. Vaccine development is typically costly and carries significant financial risk due to uncertain returns on investment in poorer regions. For example, Japanese encephalitis (JE), a leading viral cause of disability in Southeast Asia and the Western Pacific, illustrates the power of such collaborations (PATH, n.d.).

Case Example: Japanese Encephalitis Project

Element	Details
Disease	Japanese Encephalitis (JE) – a mosquito-borne viral infection mainly affecting children in Southeast Asia and Western Pacific countries.
Health Impact	Causes flu-like symptoms, seizures, coma, and permanent disability. No cure available—vaccination is the only prevention strategy.
Challenges	Weak disease surveillance, unstable vaccine supply, inadequate advocacy, and limited programmatic support.
Catalyst for Action	In 2004, PATH received a grant from the Bill & Melinda Gates Foundation to launch the JE project.
Collaborating Partners	PATH, WHO, national governments, and the Chengdu Institute of Biological Products (CDIBP) in China.
Outcomes	– Improved disease surveillance systems.
– Expanded data-driven vaccine introduction.
– Negotiated affordable public-sector pricing for the Chinese vaccine SA 14-14-2.
– Supported WHO prequalification process.
Beneficiary Countries	India, Cambodia, Sri Lanka, and North Korea.

This case highlights how PPPs foster innovation by combining public oversight with private sector agility. Importantly, they do not replace the role of existing organizations but rather enhance global health responses by accelerating the development of new tools and ensuring equitable vaccine distribution.

Response to Peer Post

Mobile health (mHealth) technologies represent a transformative approach to healthcare delivery in regions with limited access to medical facilities. Through mobile phones, healthcare workers can share health information, provide education, and monitor community health outcomes. However, barriers such as privacy concerns, literacy challenges, cultural differences, and the cost of mobile devices must be addressed to ensure effectiveness.

Collaboration among stakeholders, including governments, NGOs, and private donors, could help subsidize mobile technology to enhance access. When effectively implemented, mHealth solutions can improve health outcomes by bridging the gap between healthcare providers and remote populations.

As nursing professionals, we also recognize the broader potential of telemedicine (e-health). This approach connects resource-limited regions with advanced healthcare expertise globally. Nevertheless, barriers differ between developing and developed nations.

In developing countries: cost, weak infrastructure, and limited technical expertise are the primary challenges.
In developed countries: legal issues related to patient privacy, competing healthcare priorities, and perceived lack of demand are key obstacles.

For sustainable integration, national agencies must coordinate telemedicine initiatives, ensuring that they are context-appropriate, cost-effective, well-funded, and evaluated for long-term impact (Alajmi, Almansour, & Househ, 2013).

References

Yaïch, M. (2009). Investing in vaccines for developing countries: How public-private partnerships can confront neglected diseases. Human Vaccines, 5(6), 368–369. https://doi.org/10.4161/hv.5.6.8172

Alajmi, D., Almansour, S., & Househ, M. S. (2013). Recommendations for implementing telemedicine in the developing world. Studies in Health Technology and Informatics, 190, 118–120.